ProPharma’s team of dedicated experts is at the forefront of both existing and emerging industry trends. ProPharma’s team inspires tomorrow by leveraging rich data insights across our service lines and functional areas to develop innovative solutions that answer the most complex needs of both existing and prospective clients.
Do You Need an LPPV in the Nordic Countries?
While the Nordic countries are often viewed as a single region, pharmacovigilance (PV) requirements and local expectations can vary from country to country. Understanding where local representation is required, and where it remains optional, is essential for Marketing Authorization Holders (MAHs)...
Turning Regulatory Complexity into Predictable Study Start-Up Execution
Regulatory complexity is unavoidable in global clinical development. The differentiator is not whether organizations face complexity, it is how effectively they operationalize it. Across Europe,...
Regulatory Readiness as a Strategic Advantage in European Study Start-Up
For years, regulatory readiness was often viewed primarily as a compliance function, an operational necessity required to move clinical studies forward. Today, that perspective is no longer...
Successful Tech Transfers Require Both Strong Regulatory Strategy and Execution
Tech transfers are often treated as operational projects. In reality, the success, and especially the speed, are determined much earlier: by the clarity of your data requirements and gaps, your CMC...
Responsible AI in Medical Information: Safety, Ownership, Oversight
The medical information contact center serves as a critical communication link among clinical studies, healthcare professionals, patients, and caregivers to support clinical or treatment decisions....
Question & Answer with IVD Expert, Cortez McBerry, PhD The Future of IVDs: How Point-of-Care Testing and Diagnostic Miniaturization Are Transforming Healthcare In vitro diagnostics (IVDs) are rapidly...
ProPharma’s perspective on implementing AI-enabled applications with confidence, compliance, and control Artificial Intelligence (AI) is quickly moving from innovation pilots into core life sciences...
Five Metrics That Predict CRO Success (and How to Measure Them)
Selecting a contract research organization (CRO) is one of the highest-stakes decisions a sponsor makes during drug or device development. The right partner accelerates timelines, protects data...
FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determination Means for Manufacturers
On June 10, 2026, FDA issued a final administrative order (OTC000039) amending the OTC monograph for sunscreen drug products to include bemotrizinol as a generally recognized as safe and effective...
One of the biggest challenges in pharmacovigilance is knowing (and staying informed of) regional and country requirements for adverse event reporting. There are so many different requirements,...
Accelerating European Market Entry: The Strategic Advantage of Using FDA Approval in the UK’s IRP
The UK’s Evolving Role in Global Regulatory Strategy Since Brexit, the United Kingdom has continued to reshape its regulatory framework with a strong emphasis on innovation, agility, and accelerated...
Why Medical Information Is Critical to Adverse Event Reporting
Adverse event (AE) reporting is one of the most critical responsibilities across the pharmaceutical industry. At its core, pharmacovigilance (PV) exists to protect patient safety and maintain...
Rethinking the Role of the Medical Information Contact Center: An Untapped Resource for Medical Writing
In many organizations, teams are being asked to deliver greater value with limited resources. This has prompted a closer look at existing functions to identify where capabilities may be...
Rethinking Biometrics Resourcing in Modern Clinical Trials
Rethinking biometrics as a strategic function to improve consistency, scalability, and clinical trial performance. Biometrics has become one of the most critical components of clinical development....
The Hidden Value of Medical Information: Strengthening Brand Trust
Pharmaceutical companies are not always portrayed positively in the media or fully appreciated by customers. A common perception persists that the industry prioritizes revenue over patient...
Opening Scene: A Routine Batch Review, Or So It Seemed It started, as many GMP investigations do, with a routine batch review. But this time, the review wasn't happening on the manufacturing floor;...
Compiling and submitting a New Drug Application (NDA) submission is a complicated and intensive activity. Once you have submitted your application to FDA, you may be curious about what can you expect...
Safety Data Exchange Agreements (SDEAs) and Pharmacovigilance Agreements (PVAs) – An Overview
A Safety Data Exchange Agreement (SDEA) or Pharmacovigilance Agreement (PVA) is a legal written contract which ensures that all safety data, PV tasks and responsibilities are detailed between two or...
The FDA’s homepage contains an item in the Public Health Focus section from the Office of Communications entitled “Don’t Use Expired Medicine.” Given this mandate, I recall from many years ago the...
An Overview of the PSMF: Pharmacovigilance System Master File
What is a PSMF? The EU Pharmacovigilance System Master File (PSMF) is a legally required document created and maintained by a Marketing Authorisation Holder (MAH). Essentially, the document is a...
The Importance of the eCTD Structure for FDA Approval
The Importance of the eCTD To harmonize the process of regulatory reviews for global drug development, a unified structure was developed and implemented for electronic Common Technical Document...
The term Functional Service Provider (FSP) concept is highly regarded in the field of clinical research. With drug discovery and clinical trials becoming more complex, pharmaceutical firms and...